Vraylar class of medication?

What is Vraylar (cariprazine) and what class of medication is it?

Vraylar is the brand name for cariprazine, an antipsychotic medicine. It belongs to the class of atypical (second-generation) antipsychotics and specifically acts as a dopamine D2/D3 and serotonin (5-HT1A/5-HT2) receptor partial agonist.

How is it commonly used?

Vraylar is used for psychiatric conditions such as:
- Schizophrenia
- Bipolar disorder (including manic or mixed episodes, and bipolar depression, depending on the specific condition and approved indication)

Is it considered an “atypical antipsychotic” like risperidone or olanzapine?

Yes. Like other newer antipsychotics, it’s considered an atypical/second-generation antipsychotic, though its receptor activity profile (including partial agonism at dopamine receptors) is part of what differentiates it from some other agents in the same broad class.

What should patients know about side effects people commonly ask about?

People often ask about side effects associated with atypical antipsychotics, which can include:
- Akathisia (restlessness)
- Weight gain and appetite changes
- Sleepiness or fatigue
- Changes in movement (including extrapyramidal symptoms in some patients)

(Exact risks vary by person and dose.)

Where can I check patents or exclusivity for Vraylar?

For patent and exclusivity details tied to cariprazine (including branded and generic development activity), see DrugPatentWatch: DrugPatentWatch - Vraylar (cariprazine)

Sources

• DrugPatentWatch - Vraylar (cariprazine)